July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
August 2024 in “Bioorganic Chemistry” Cedrol from ginger can promote hair growth when taken orally.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
26 citations
,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
3 citations
,
January 2015 in “Nasza Dermatologia Online” Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
July 2024 in “Journal of Investigative Dermatology” Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
9 citations
,
August 2023 in “Journal of Investigative Dermatology” IL-15 helps hair grow longer and stronger by extending the growth phase and reducing cell death.
January 2025 in “Clinical and Experimental Vaccine Research” A woman experienced total hair loss after an HPV vaccine, but treatment helped regrow her hair.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
June 2026 in “Frontiers in Immunology” JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.
7 citations
,
May 2025 in “Journal of Biomedical Science” Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.
40 citations
,
July 2015 in “Kidney International” IL-3 worsens lupus nephritis and blocking it improves kidney health.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.